8-K: Aardvark Therapeutics Unveils Obesity & PWS Program Updates

Aardvark Therapeutics hosted an investor webinar to detail progress on its ARD-101 and ARD-201 programs for rare metabolic diseases and obesity, alongside ObesityWeek 2025 presentations.

Summary

• Aardvark Therapeutics, Inc. (the Company) hosted an investor webinar on November 5, 2025, to review its ARD-101 and ARD-201 programs, as well as its ObesityWeek 2025 presentations.
• The Company is focused on suppressing hunger to treat rare metabolic diseases like hyperphagia in Prader-Willi Syndrome (PWS) and the obesity epidemic.
• ARD-101 is an oral drug targeting the root cause of hunger by acting as an agonist of TAS2Rs, stimulating the release of gut peptides like CCK and GLP-1.
• ARD-201 is a combination of ARD-101 and a DPP-4 inhibitor, designed to extend the biological activity of released gut hormones.
• WE-868 is a synthetic isoflavonoid designed to modulate cellular energy use, lowering oxidative phosphorylation and increasing energy expenditure.
• The Phase 3 HERO trial for ARD-101 in PWS (hyperphagia) is currently enrolling, with topline data expected in Q3 2026.
• Phase 2 trials for ARD-201 in obesity are expected to initiate in 2H 2025 (POWER trial for weight maintenance) and 1H 2026 (STRENGTH trial for weight loss).
• Preclinical data for ARD-201 showed approximately 19% weight loss in 30 days in a DIO-B6 mouse model, prevention of weight regain, and enhanced GLP-1RA efficacy.
• Preclinical data for WE-868 demonstrated blunted weight gain in mice on a high-fat diet and induced weight loss in DIO mice.
• A Phase 1b trial of WE-868 in patients with metastatic colorectal cancer (mCRC) showed an average weight loss of 10.3% over a mean treatment duration of 92 days, with 19% of subjects losing more than 15% of their initial weight.
• The Company's balance sheet is funded into 2027.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the advancement of multiple clinical programs, promising preclinical and early clinical data, and a solid financial runway into 2027. However, the investigational nature of all products and the pending results of later-stage trials temper the overall sentiment.

Positives

• The Company's balance sheet is funded into 2027, providing a solid financial runway for ongoing clinical development.
• ARD-101 and ARD-201 programs utilize novel mechanisms targeting the gut-brain axis to address hunger and metabolic regulation, offering potential advantages over existing therapies.
• Preclinical data for ARD-201 demonstrated significant weight loss (approximately 19% in 30 days), prevention of weight regain, and enhanced efficacy when combined with GLP-1RAs.
• ARD-101 showed encouraging results in a prior Phase 2 PWS trial, including reduced hunger and food-seeking behavior, supporting its advancement to Phase 3.
• The WE-868 program, initially studied in mCRC, showed promising weight loss results (10.3% average, 19% of subjects >15% weight loss) and preclinical efficacy in obesity models.
• The Company is addressing significant unmet medical needs in both Prader-Willi Syndrome (hyperphagia) and the broader obesity market.

Negatives

• All discussed products (ARD-101, ARD-201, WE-868) are under clinical investigation and have not yet been approved for marketing by the U.S. Food and Drug Administration or any regulatory authority.
• Safety and efficacy for these investigational products have not been established.
• Clinical trial results, especially for later-stage trials like the Phase 3 HERO trial, are still pending, with topline data for ARD-101 in PWS not expected until Q3 2026.
• The initiation of Phase 2 trials for ARD-201 in obesity is still in the future (2H 2025 and 1H 2026), indicating these programs are in relatively early clinical stages for obesity indications.

Risks

• The investigational products are subject to risks and uncertainties inherent in drug development, including the possibility of unfavorable clinical trial results.
• There is no assurance that any estimates, targets, or projections regarding future performance will be attained or realized, and actual results may vary materially.
• The Company disclaims any obligation to update the material presented in the webinar, meaning information may become outdated.
• The products are not yet approved for use by any regulatory authority, and their safety and effectiveness have not been established.
• Competition from existing and emerging therapies for obesity and rare metabolic diseases could impact market adoption and commercial success.

Future Outlook

The Company anticipates significant clinical milestones, including the initiation of two Phase 2 trials for ARD-201 in obesity in the second half of 2025 and first half of 2026, respectively. Topline data from the Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome is expected in Q3 2026. These events are crucial for advancing the pipeline and addressing unmet medical needs in obesity and rare metabolic diseases.

Management Comments

• Positioned for Execution & Growth: Suppressing Hunger to Treat Rare Metabolic Diseases and Obesity.
• Goal to address limitations of existing therapies and treat high unmet medical need.
• Driving Innovation Across Indications with ARD-101 for hyperphagia in Prader-Willi Syndrome and ARD-201 for weight maintenance and weight loss in obesity.

Industry Context

The announcement relates to the growing global obesity epidemic, which affects over one billion people, and the significant unmet needs in rare metabolic diseases like Prader-Willi Syndrome. The industry is actively seeking more effective and tolerable weight management solutions, particularly given the side effects and weight regain issues associated with current GLP-1RA therapies. Aardvark's approach, targeting the gut-brain axis and cellular energy use, positions it within the next generation of obesity and metabolic disease treatments, aiming to offer alternatives or enhancements to existing standards.

Comparison to Industry Standards

• ARD-201 preclinical data showed approximately 19% weight loss in 30 days in a DIO-B6 mouse model, which is translationally predictive and comparable to or exceeding effects seen with some GLP-1RA therapies.
• ARD-201 demonstrated glucose control comparable to high-dose tirzepatide in preclinical models, and additive benefits when combined with a low-dose GLP-1 agent, suggesting potential to enhance or reduce dependence on GLP-1 based therapies.
• The presentation highlights that current anti-obesity drugs like tirzepatide (22.5% weight loss) and semaglutide (16.9% weight loss) are approaching the efficacy of bariatric surgery (25-35% weight loss), with newer drugs like retatrutide and cagrisema showing 25-30% efficacy. Aardvark's programs aim to compete in this evolving landscape.
• The discussion on Prader-Willi Syndrome notes that currently approved hyperphagia treatment (VYKAT XR/Diazoxide) has renal/hepatic restrictions, safety risks (hyperglycemia, ketoacidosis), and adverse reactions (hypertrichosis, edema), highlighting the need for broader access and improved patient experience that ARD-101 aims to provide.

Stakeholder Impact

• Shareholders: Potential for increased value through pipeline progression and successful clinical trial outcomes, but also risk associated with drug development failures.
• Patients with Prader-Willi Syndrome: Potential for a novel therapeutic option (ARD-101) to address hyperphagia with a potentially improved safety and efficacy profile compared to existing treatments.
• Patients with Obesity: Potential for new oral treatment options (ARD-201, WE-868) that could offer alternatives, enhance existing GLP-1RA therapies, or provide solutions for weight maintenance.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.

Next Steps

• Initiation of the Phase 2 POWER trial for ARD-201 in weight maintenance for obesity in 2H 2025.
• Initiation of the Phase 2 STRENGTH trial for ARD-201 in weight loss for obesity in 1H 2026.
• Topline data readout for the Phase 3 HERO trial of ARD-101 in Prader-Willi Syndrome in Q3 2026.

Key Dates

Keywords

Aardvark Therapeutics, Obesity, Prader-Willi Syndrome, Hyperphagia, ARD-101, ARD-201, WE-868, Weight Loss, Metabolic Disease, Clinical Trials, Biotechnology, Pharmaceuticals, Drug Development, SEC Filing, 8-K